1 October 2023 - The October 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The October issue of the Schedule includes a few major new/revised listings:

• Bimekizumab (Bimzelx) - new medicine
• Carfilzomib (Kyprolis) - new indication
• Deucravicitinib (Sotyktu) - new medicine
• Enfortumab vedotin (Padcev) - new medicine
• Fosnetupitant chloride hydrochloride with palonosetron hydrochloride (Akynzeo IV) - new formulation
• Insulin aspart (Fiasp) - new formulation (continued listing)
• Onasemnogene abeparvovec (Zolgensma) - new indication
• Pembrolizumab (Keytruda) - new indication
• Risdiplam (Evrysdi) - new indication

Read Summary of PBS changes